SCHEMBL861279

SCHEMBL861279

CC(C)(C)Cc1ccc2ncc3ccccc3c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.51
GPR3 P46089 1/20 0.51
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
DUSP10 Q9Y6W6 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPT P10636 3/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
RECQL P46063 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDPK1 O15530 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CG P48736 1/20 0.35
TLR9 Q9NR96 1/20 0.35
EGFR P00533 1/20 0.35
SLC22A12 Q96S37 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11292855 0.83 KDM4E (0.53) KDM4EGPR3MEN1KMT2ACYP3A4
SCHEMBL8574548 0.83 KDM4E (0.56) KDM4EGPR3MEN1KMT2ACYP3A4
Bromide SCHEMBL5777889 0.81 KDM4E (0.55) KDM4EGPR3MEN1KMT2ACYP3A4
SCHEMBL17229159 0.76 KDM4E (0.56) KDM4EGPR3MEN1KMT2ACYP3A4
SCHEMBL861436 0.76 APP (0.43)
SCHEMBL861261 0.76 KDM4E (0.39) KDM4EMEN1KMT2ACYP3A4MAPT
SCHEMBL22951467 0.75 NQO2 (0.48) KDM4EMEN1KMT2AMAPTNPC1
SCHEMBL6151918 0.75 KDM4E (0.64) KDM4EGPR3MEN1KMT2ACYP3A4
SCHEMBL10727445 0.74 KDM4E (0.46) KDM4EGPR3MEN1KMT2ACYP3A4
SCHEMBL840612 0.74 KDM4E (0.62) KDM4EGPR3MEN1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8142909-B2 Blue phosphorescent imidazophenanthridine materials UNIVERSAL DISPLAY CORPORATION (US) 2012-03-27 US disclosed
US-8142909-B2 Blue phosphorescent imidazophenanthridine materials UNIVERSAL DISPLAY CORPORATION (US) 2012-03-27 US disclosed
WO-2008156879-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION (US) 2008-12-24 WO disclosed
US-20080297033-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION 2008-12-04 US disclosed
US-20080297033-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080297033-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS IK, CRY1, MAP1LC3C KDM4E 3612/4885GPR3 1714/4885MEN1 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.